Cargando…

Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy

The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor immunotherapy. PD-L1 is overexpressed on the surface of tumor cells and inhibits T cell activation upon binding to PD⁃1 on the surface of T ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Chong, Zhang, Lening, Chang, Xin, Qin, Dongliang, Zhang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405826/
https://www.ncbi.nlm.nih.gov/pubmed/37554324
http://dx.doi.org/10.3389/fimmu.2023.1230135
_version_ 1785085618942902272
author Feng, Chong
Zhang, Lening
Chang, Xin
Qin, Dongliang
Zhang, Tao
author_facet Feng, Chong
Zhang, Lening
Chang, Xin
Qin, Dongliang
Zhang, Tao
author_sort Feng, Chong
collection PubMed
description The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor immunotherapy. PD-L1 is overexpressed on the surface of tumor cells and inhibits T cell activation upon binding to PD⁃1 on the surface of T cells, resulting in tumor immune escape. The therapeutic strategy of targeting PD-1/PD-L1 involves blocking this binding and restoring the tumor-killing effect of immune cells. However, in clinical settings, a relatively low proportion of cancer patients have responded well to PD-1/PD-L1 blockade, and clinical outcomes have reached a bottleneck and no substantial progress has been made. In recent years, PD-L1 post-translation modifications (PTMs) have gradually become a hot topic in the field of PD-L1 research, which will provide new insights to improve the efficacy of current anti-PD-1/PD-L1 therapies. Here, we summarized and discussed multiple PTMs of PD-L1, including glycosylation, ubiquitination, phosphorylation, acetylation and palmitoylation, with a major emphasis on mechanism-based therapeutic strategies (including relevant enzymes and targets that are already in clinical use and that may become drugs in the future). We also summarized the latest research progress of PTMs of PD-L1/PD-1 in regulating immunotherapy. The review provided novel strategies and directions for tumor immunotherapy research based on the PTMs of PD-L1/PD-1.
format Online
Article
Text
id pubmed-10405826
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104058262023-08-08 Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy Feng, Chong Zhang, Lening Chang, Xin Qin, Dongliang Zhang, Tao Front Immunol Immunology The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor immunotherapy. PD-L1 is overexpressed on the surface of tumor cells and inhibits T cell activation upon binding to PD⁃1 on the surface of T cells, resulting in tumor immune escape. The therapeutic strategy of targeting PD-1/PD-L1 involves blocking this binding and restoring the tumor-killing effect of immune cells. However, in clinical settings, a relatively low proportion of cancer patients have responded well to PD-1/PD-L1 blockade, and clinical outcomes have reached a bottleneck and no substantial progress has been made. In recent years, PD-L1 post-translation modifications (PTMs) have gradually become a hot topic in the field of PD-L1 research, which will provide new insights to improve the efficacy of current anti-PD-1/PD-L1 therapies. Here, we summarized and discussed multiple PTMs of PD-L1, including glycosylation, ubiquitination, phosphorylation, acetylation and palmitoylation, with a major emphasis on mechanism-based therapeutic strategies (including relevant enzymes and targets that are already in clinical use and that may become drugs in the future). We also summarized the latest research progress of PTMs of PD-L1/PD-1 in regulating immunotherapy. The review provided novel strategies and directions for tumor immunotherapy research based on the PTMs of PD-L1/PD-1. Frontiers Media S.A. 2023-07-24 /pmc/articles/PMC10405826/ /pubmed/37554324 http://dx.doi.org/10.3389/fimmu.2023.1230135 Text en Copyright © 2023 Feng, Zhang, Chang, Qin and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Feng, Chong
Zhang, Lening
Chang, Xin
Qin, Dongliang
Zhang, Tao
Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
title Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
title_full Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
title_fullStr Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
title_full_unstemmed Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
title_short Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
title_sort regulation of post-translational modification of pd-l1 and advances in tumor immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405826/
https://www.ncbi.nlm.nih.gov/pubmed/37554324
http://dx.doi.org/10.3389/fimmu.2023.1230135
work_keys_str_mv AT fengchong regulationofposttranslationalmodificationofpdl1andadvancesintumorimmunotherapy
AT zhanglening regulationofposttranslationalmodificationofpdl1andadvancesintumorimmunotherapy
AT changxin regulationofposttranslationalmodificationofpdl1andadvancesintumorimmunotherapy
AT qindongliang regulationofposttranslationalmodificationofpdl1andadvancesintumorimmunotherapy
AT zhangtao regulationofposttranslationalmodificationofpdl1andadvancesintumorimmunotherapy